Lv3
298 积分 2024-09-07 加入
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
1个月前
已完结
Deucravacitinib Inhibits Synovial Fibroblast Activation Via TYK2/STAT3 and PI3K/Akt Signaling Pathway
2个月前
已完结
TYK2 mediates neuroinflammation in Alzheimer’s disease brains with TDP-43 pathology
2个月前
已完结
Deucravacitinib-induced cutaneous hypersensitivity reactions
2个月前
已完结
A Review of Phase III and Long‐Term Data for Deucravacitinib for Plaque Psoriasis
2个月前
已完结
Targeted protein degradation in autoimmune diseases: from mechanisms to therapeutic breakthroughs
2个月前
已完结
Dermatomyositis: Clinical features and pathogenesis
3个月前
已完结
Dermatomyositis: Clinical features and pathogenesis
3个月前
已完结
Metabolic traits of T cells and the implications in autoimmune diseases
4个月前
已关闭
Successful Treatment of Pityriasis Rubra Pilaris With Deucravacitinib
4个月前
已关闭
皖公网安备34019202002308
